SBC Medical Group Holdings Inc. has completed a strategic investment in OrangeTwist, a U.S.-based medspa chain specializing in non-invasive aesthetic treatments, marking the Japanese company's official entry into the American market. The partnership enables SBC Medical, which manages more than six million patient visits annually through 258 affiliated clinics worldwide, to leverage OrangeTwist's 24 locations across six U.S. states while pursuing joint operations that combine OrangeTwist's advanced management system with SBC's operational expertise.
The medical aesthetics industry is forecast to grow from $34 billion today to $48 billion by 2030, driven by demand for non-surgical treatments including injectables, fillers, laser treatments and body contouring. SBC will provide funding and professional know-how to help OrangeTwist enhance its offerings and address "white space" in the U.S. medspa market—cities with high demand for services but few competitors. By combining resources, the companies plan to secure first-mover advantages in these underserved markets.
Stephen Rodgers, global head of planning and strategy at SBC Medical, told Benzinga that the company plans additional strategic investments to expand in the U.S., seeking local partnerships rather than replicating its Japanese model. Beyond joint clinic operations, OrangeTwist and SBC Medical plan to jointly develop branded products and sell existing products in each other's spas.
SBC's expansion strategy extends beyond medical aesthetics into the broader longevity industry, which is shifting from increasing lifespan to boosting "healthspan" through personalized, preventative and tech-driven solutions. According to Gabelli Research, the global anti-aging market, valued at approximately $85 billion in 2025, is expected to surpass $120 billion by 2030, growing at a CAGR of 7% from 2025-2030. North America accounts for approximately 30% of this market, while Asia shows robust growth driven by beauty-conscious consumers and an aging population.
The company is positioned to capitalize on demographic trends, including the 4.1 million Americans turning 65 annually through 2027, by offering AI-powered diagnostics, GLP-1 weight-loss drugs, regenerative therapies like stem cells, and other longevity-related services through its existing infrastructure. SBC's global expansion strategy rests on three core tenets: partnering with high-performing regional operators with scalable business models, deploying SBC's expertise to drive efficiencies and optimize operating performance, and securing first-mover advantages to support innovation and margin expansion.
While establishing a U.S. foothold through OrangeTwist, SBC Medical continues expanding in Japan and Southeast Asia, implementing standardized services across Thailand and Singapore to ensure consistent quality and pricing. The company's partnership model, which includes training staff, providing better pricing for medical equipment, and offering management services, creates a replicable framework for global growth. This approach enables SBC to build a single, trusted brand providing aesthetic beauty services worldwide while addressing growing demand for natural-looking treatments with minimal recovery times across both Western and Asian markets.
